The FDA has approved a supplement to the new drug application for Ozurdex, the dexamethasone intravitreal implant held by AbbVie. The notice reached the regulatory watch on 8 October 2026; it does not give the approval date or say what the supplement changes.
This is an ophthalmic product and the action does not affect respiratory prescribing. It is reported here because the regulatory sweep routed it to this desk. The one point of overlap is steroid exposure: patients with asthma or COPD who also receive intraocular steroids carry cumulative risks of cataract and raised intraocular pressure. Its status with CDSCO is not stated.
- This is an FDA action on an eye implant; it does not change respiratory practice.
- The content of the supplement is not stated in the notice.
- When reviewing steroid burden in chronic airway disease, ask about eye injections or implants as well as inhaled and oral steroids.
- Indian regulatory status is not addressed by this notice.
Why it matters
Steroid exposure from several routes adds up, and eye treatments are often missing from the respiratory drug history.
Don't overread it
An administrative supplement on an ophthalmic product, not a respiratory safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free